Ideaya Biosciences price target raised to $58 from $52 at Wedbush

Wedbush raised the firm’s price target on Ideaya Biosciences (IDYA) to $58 from $52 and keeps an Outperform rating on the shares. The firm notes the company reported topline data from the Phase 2/3 OptimUM-02 study. On the call, management indicated adverse events continue to be well managed, in line with prior studies. Additional data from the study is expected to be published at a major medical meeting in 2026, Wedbush says.